• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Lirentelimab may be effective for treatment of eosinophilic gastrointestinal disease

byThomas SuandDeepti Shroff, DMD, MS
November 3, 2020
in Chronic Disease, Gastroenterology
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. Patients who received AK002, lirentelimab, had far greater reductions in both gastrointestinal eosinophil burden and gastrointestinal symptoms compared to those who received placebo.

2. These between-group differences emerged immediately following the first dose and persisted across the entire 4-month study.

Evidence Rating Level: 1 (Excellent)

Study Rundown: While eosinophilic esophagitis has become well-characterized over the past decade, recent studies have shown that eosinophilic gastroenteritis may remain underdiagnosed despite causing significant quality-of-life impairments. Diet modification and corticosteroids are commonly used for management of the condition, but no specific pharmacologic therapies have yet been approved. AK002 (lirentelimab) is a first-in-class, humanized, non-fucosylated IgG1 anti–Siglec-8 monoclonal antibody that has been shown to selectively deplete eosinophils and inhibit mast-cell activation, thus reducing degranulation, secretion of inflammatory mediators, and recruitment of other immune cells. In this study, adults with eosinophilic gastritis or duodenitis received high or low dosage AK002 or placebo at monthly intervals. By day 99, two weeks after the fourth and final dose, the combined AK002 group had experienced a significantly greater reduction in gastrointestinal eosinophil count versus placebo. A histologic response was observed in over 90% of patients who received AK002 and only 15% of those who received placebo. Interestingly, patients with concomitant esophageal eosinophilia also had a far greater rate of esophageal histologic remission when treated with AK002, likely owing to a rapid decrease in blood absolute eosinophil count that was not observed in the placebo group. The combined AK002 group also had over twice as much improvement in total gastrointestinal symptom score compared to placebo. Infusion-related reactions were generally mild-to-moderate and occurred far more frequently among those who received AK002, but serious adverse events occurred at similar rates between groups. The primary limitation of this study was the small sample size; further research should be done to confirm the safety and efficacy of this therapeutic agent.

Click here to read the study in the NEJM (New England Journal of Medicine)

Relevant Reading: AK002, a Humanized Sialic Acid-Binding Immunoglobulin-Like Lectin-8 Antibody that Induces Antibody-Dependent Cell-Mediated Cytotoxicity against Human Eosinophils and Inhibits Mast Cell-Mediated Anaphylaxis in Mice

RELATED REPORTS

Mezagitimab appears safe and potentially effective for persistent immune thrombocytopenia

Dazukibart is effective in reducing disease activity in adults with refractory dermatomyositis

In-Depth [randomized controlled trial]: In this phase 2 trial conducted at 17 sites in the United States, 65 adults with moderate-to-severe symptoms of eosinophilic gastrointestinal disease were randomly assigned in a 1:1:1 ratio to receive four monthly intravenous infusions of low-dose AK002 (0.3, 1, 1, and 1 mg per kg), high-dose AK002 (0.3, 1, 3, and 3 mg per kg), or placebo. Of the 65, 10 had a diagnosis of gastritis, 25 had a diagnosis of duodenitis, and 30 had concurrent gastritis and duodenitis. Patients with celiac disease, active Helicobacter pylori infection, or inflammatory bowel disease were excluded. The groups had similar clinical characteristics at baseline with the exception of peripheral blood eosinophil count, which was numerically higher in the combined AK002 group. At day 99, the AK002 group had a change in the gastrointestinal eosinophil count of −95%, as compared with 10% in the placebo group (least-squares mean difference, −105 percentage points; 95% CI, −128 to −83; P<0.001). AK002 treatment produced a histologic response (<30 gastrointestinal eosinophils per high-power field) in 37 patients while only 3 patients in the placebo group experienced the same effect. The first secondary endpoint of treatment response (defined as both a >30% reduction in total symptom score and a >75% reduction in gastrointestinal eosinophil count) was observed in 27 patients in the AK002 groups versus only 1 in the placebo group (percentage difference, 64; P<0.001). Lastly, patients in the AK002 groups had greater improvements in all 8 components of the 36-Item Short Form Survey quality-of-life questionnaire compared to those who received the placebo.

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: AK002eosinophilic gastrointestinal diseaseLirentelimabmonoclonal antibody
Previous Post

Genetic susceptibility for severe Covid-19 symptoms with respiratory failure

Next Post

Pediatric hospitalizations decline during the COVID-19 pandemic

RelatedReports

Blood disorders collage: a round microscope-style view of red blood cells and small spiky platelets beside a glass slide
Hematology

Mezagitimab appears safe and potentially effective for persistent immune thrombocytopenia

April 9, 2026
Dermatomyositis collage: an engraved bundle of muscle fibers beside a cut-away block of skin layers and a wide sun hat
Chronic Disease

Dazukibart is effective in reducing disease activity in adults with refractory dermatomyositis

February 12, 2025
Inflammatory bowel disease collage: engraved small and large intestines beside a cup of peppermint tea and mint leaves
Chronic Disease

Mirikizumab is safe and effective in patients with moderate-to-severe Crohn’s disease

February 6, 2025
Combined immunotherapy may improve survival in metastatic pancreatic cancer
Chronic Disease

Denosumab may increase risk of major adverse cardiovascular events but reduce fracture risk in patients receiving dialysis

January 13, 2025
Next Post

Pediatric hospitalizations decline during the COVID-19 pandemic

#VisualAbstract: Evolocumab successfully reduced LDL levels in pediatric patients

#VisualAbstract: COVID-19 infection in late pregnancy associated with adverse birth outcomes

Women with pregnancy-associated melanoma at greater risk of metastasis, recurrence

Ultrasound effective for identifying in-transit metastases in patients with cutaneous melanoma

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Few patients had ED lumbar CT or MRI within 30 days after low-acuity back-pain radiography at urgent care centers
  • A 34-circular RNA blood signature predicted Alzheimer’s disease progression and improved prediction when combined with pTau217
  • Inhaled corticosteroids do not improve outcomes in sickle cell disease patients without asthma
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.